Olr354 inhibitors represent a specialized category of chemical compounds that are defined by their ability to selectively inhibit the activity of the olfactory receptor 354 (Olr354). Olfactory receptors, a subset of G protein-coupled receptors (GPCRs), are primarily recognized for their role in the detection of odorants, facilitating the sense of smell. However, research has revealed that these receptors, including Olr354, are expressed beyond the olfactory epithelium, indicating potential roles in various physiological processes. Olr354 inhibitors are designed to target the specific conformational states of this receptor, effectively blocking its signaling pathways. The inhibition is typically achieved through the binding of the inhibitor to the receptor's active site, thereby preventing the interaction between the receptor and its natural ligands. This binding is often characterized by a high degree of specificity, ensuring that the inhibition of Olr354 does not interfere with the function of other closely related olfactory receptors or GPCRs.
The design and development of Olr354 inhibitors are guided by detailed structural studies of the receptor, often employing techniques such as X-ray crystallography or cryo-electron microscopy. These methods allow for the precise mapping of the receptor's binding site and the identification of key residues involved in ligand recognition. Computational modeling also plays a crucial role in predicting the binding affinity and selectivity of potential inhibitors. The chemical diversity within this class of inhibitors is extensive, encompassing a range of molecular scaffolds that provide varying degrees of potency and selectivity. Moreover, the structure-activity relationships (SAR) of these compounds are thoroughly explored to optimize their inhibitory properties. The study of Olr354 inhibitors not only enhances our understanding of the molecular dynamics of olfactory receptors but also contributes to the broader knowledge of GPCR function and regulation. This knowledge is pivotal in unraveling the complex signaling networks in which these receptors are involved, offering insights into their non-olfactory roles and their broader biological significance.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
CH5424802 | 1256580-46-7 | sc-364461 sc-364461A | 5 mg 50 mg | $191.00 $902.00 | ||
Targets ALK, potentially affecting signaling in non-small cell lung cancer with specific mutations. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Inhibits VEGFR, EGFR, and RET tyrosine kinases, potentially affecting angiogenesis and tumor growth. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
Multi-kinase inhibitor, might influence angiogenesis and cell proliferation by targeting VEGFR and PDGFR. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Inhibits multiple protein kinases, potentially affecting tumor growth and angiogenesis. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $92.00 $204.00 | 1 | |
Targets MET, VEGFR, and AXL, potentially affecting tumor growth and metastasis. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $193.00 $510.00 $1072.00 | 4 | |
Multi-kinase inhibitor, could affect cell signaling and angiogenesis by targeting PDGFR and VEGFR. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
BCR-ABL tyrosine kinase inhibitor, potentially effective in chronic myelogenous leukemia. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Bruton's tyrosine kinase inhibitor, might affect B-cell signaling in certain hematologic cancers. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $172.00 $964.00 | 2 | |
Inhibits BCR-ABL and other tyrosine kinases, potentially effective in resistant chronic myeloid leukemia. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $180.00 $315.00 | 2 | |
Inhibits FGFR, PDGFR, and VEGFR, potentially affecting fibrosis and tumor angiogenesis. | ||||||